News

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

Cataract surgery is not neutral for the vitreous.

Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models, but the authors are open about where joint learning gave ground.

Few people starting tamoxifen require an ophthalmic evaluation during the following year.

Clinical Forum cases examine symptoms, progression, and treatment response.

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.

Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery.

October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.

Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's vision-enhancement features.

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Andrew G. Lee, MD, and Drew Carey, MD, break down the visual safety of flow-diverting stents for carotid-ophthalmic aneurysms.

Christopher J. Rapuano, MD, discusses emergency eye care access, retina advances and responsible AI use in ophthalmology.

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.

Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina cases.

Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial results.

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.

Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.

Isa S. K. Mohammed, MD, explains how he matches patients to PRK, LASIK, SMILE, or phakic IOLs and how prior surgery affects IOLs.

AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Christina Y. Weng, MD, MBA, FASRS; Michael A. Singer, MD, and Isa S. K. Mohammed, MD, point to early retinal care, corticosteroid training, and regulation and waste.